BioProject

The epigenetic regulator TET2 is frequently mutated in hematological diseases. More...

The epigenetic regulator TET2 is frequently mutated in hematological diseases. Mutations have been shown to arise in hematopoietic stem cells early in disease development, lead to altered DNA methylation landscapes and to an increased risk of hematopoietic malignancy. Here, we show by genome-wide mapping of TET2 binding sites in different cell types that TET2 localizes to regions of open chromatin and cell-type specific enhancers. We find that deletion of Tet2 in native hematopoiesis as well as fully transformed Acute Myeloid Leukemia (AML) results in changes in transcription factor (TF) activity within these regions, and we provide evidence that loss of TET2 leads to attenuation of chromatin binding of members of the basic helix-loop-helix (bHLH) TF family. Together, these findings demonstrate that TET2 activity shapes the local chromatin environment at enhancers to facilitate TF binding and provide a compelling example of how epigenetic dysregulation can affect gene expression patterns and drive disease development. Overall design: ChIP-seq analysis of embryonic stem cells expressing wildtype TET2 or a FLAG-tagged TET2 expressed from the endogenous Tet2 locus. TET2 binding sites were defined by enrichment over non-specific ChIP enriched regions identified in Tet2 knockout cells or parental cells without FLAG-tagged TET2. Less...